Sti1 Is a Novel Activator of the Ssa Proteins*

Harald Wegele {ddagger} §, Martin Haslbeck {ddagger}, Jochen Reinstein ¶ and Johannes Buchner {ddagger} ||

From the {ddagger}Institut für Organische Chemie & Biochemie, Technische Universität München, Lichtenbergstrasse 4, 85747 Garching, Germany and the Max-Planck-Institut für Molekulare Physiologie, Abteilung physikalische Biochemie, Otto-Hahn-Strasse 11, 44227 Dortmund, Germany

Received for publication, February 13, 2003 , and in revised form, April 23, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The molecular chaperones Hsp70 and Hsp90 are involved in the folding and maturation of key regulatory proteins in eukaryotes. Of specific importance in this context is a ternary multichaperone complex in which Hsp70 and Hsp90 are connected by Hop. In Saccharomyces cerevisiae two components of the complex, yeast Hsp90 (yHsp90) and Sti1, the yeast homologue of Hop, had already been identified, but it remained to be shown which of the 14 different yeast Hsp70s are part of the Sti1 complex and what were the functional consequences resulting from this interaction. With a two-hybrid approach and co-immunoprecipitations, we show here that Sti1 specifically interacts with the Ssa group of the cytosolic yeast Hsp70 proteins. Using purified components, we reconstituted the dimeric Ssa1-Sti1 complex and the ternary Ssa1-Sti1-yHsp90 complex in vitro. The dissociation constant between Sti1 and Ssa1 was determined to be 2 orders of magnitude weaker than the affinity of Sti1 for yHsp90. Surprisingly, binding of Sti1 activates the ATPase of Ssa1 by a factor of about 200, which is in contrast to the behavior of Hop in the mammalian Hsp70 system. Analysis of the underlying activation mechanism revealed that ATP hydrolysis is rate-limiting in the Ssa1 ATPase cycle and that this step is accelerated by Sti1. Thus, Sti1 is a potent novel effector for the Hsp70 ATPase.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Molecular chaperones are a diverse set of functionally related proteins that are involved in protein folding in the cell. An important feature in this context are dynamic interactions of various components of the chaperone machinery. Two of the most abundant chaperones found in the eukaryotic cell are Hsp70 and Hsp90. The Hsp70 and Hsp90 chaperones cooperate in the formation and maintenance of protein structures of a set of target proteins in vivo (17).

In contrast to Hsp70, which is involved in a wide variety of functions including folding of nascent polypeptide chains (8, 9), Hsp90 seems to be a more specialized folding factor (1015). The in vivo substrate proteins of Hsp90 include key regulatory factors such as kinases and steroid hormone receptors among others (2, 3, 16, 17). In eukaryotes, Hsp90 fulfills its chaperone function in complex with a large number of cofactors (1820). Two of them were identified as Hsp70 and Hop in higher eukaryotes (21, 22). A complex consisting of Hsp70, Hop, and Hsp90 is of central importance for the Hsp90 chaperone cycle, because it is able to activate steroid hormone receptors for steroid hormone binding in vitro (23). Hop/Sti1 is a unique co-chaperone consisting mainly of three tetratricopeptide repeat (TPR)1 domains. TPRs are helical modules that mediate interactions between proteins (24). In the case of Hop, its TPR domains can bind to the C-terminal ends of both Hsp70 and Hsp90 (25), thus providing a physical link between the Hsp70 and Hsp90 chaperone machinery (26, 27). Despite its importance for the Hsp90 cycle, the composition and function of this complex are still ill-defined.

Using purified components, it had been shown previously that yHsp90 and Sti1 form a binary complex in which Sti1 inhibits the ATPase of yHsp90 (28). However, neither the question of whether in addition to the Ssa class (29) any of the nine cytosolic Hsp70 proteins in yeast is incorporated into the Sti1-yHsp90 complex nor the functional consequences of this interaction had been addressed.

These nine Hsp70s can be divided into the four subfamilies: Ssa, Ssb, Sse, and Ssz (Ss denotes stress seventy-related; a, b, e, and z indicate the subfamily) (8). The Ssa subfamily, which is the only essential Hsp70 family in the cytosol, comprises four members (Ssa1–Ssa4). The expression of at least one of the four Ssa proteins is essential for viability (30). The Ssa1 gene is expressed at high levels at physiological temperature; in addition, its expression is stimulated ~10-fold after a temperature shift to 37 °C, whereas Ssa2 is expressed at the same level at all temperatures (30). Ssa3 and Ssa4 are expressed at extremely low levels at physiological temperature, but after a temperature upshift, the amounts of Ssa3 and Ssa4 mRNAs increase severalfold (8). In contrast to the Ssa proteins, which are soluble in the cytosol, Ssb1 and Ssb2 are associated with nascent polypeptides of translating ribosomes (3133). Similarly, Ssz1 forms a ribosome-associated complex with the Hsp40 protein Zuo1. This Ssz1-Zuo1 complex stimulates the mitochondrial translocation of ribosome-nascent chain complexes (3436).

Finally, Sse1 and Sse2 are up-regulated severalfold under heat shock conditions. Under normal growth conditions, Sse1 is present at moderate levels, and Sse2 is present at very low levels (37).

To analyze the function of the Hsp70·Sti1·Hsp90 complex from yeast, we first set out to identify the Hsp70 components. We show that the Ssa proteins are the only Hsp70 component of the complex and that Sti1, unlike Hop in the mammalian Hsp90 multichaperone complex, is a novel regulator for their ATPase activity.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Yeast Strains, Culture Media, and General Methods—All strains except for GS 115, which is a Pichia pastoris strain, are Saccharomyces cerevisiae strains. Strains used in this study have the following geno-types: Y190, MATa ura3–52 his3–200 ade2–101 lys2–801 trp1–901 leu2–3,112 gal4{Delta} gal80{Delta} cyhr2 LYS2::GAL1UAS-HIS3TATA-HIS3 MEL1 URA3:: GAL1UAS-GAL1TATA-lacZ; W303, MATa ade2–1, leu2–3, 112 his3–11, and 15 trp1–1 ura3–1 can1–100; CN11a, MATa {Delta}trp1 lys1 lys2 ura3–52 leu2–3,112 his3–11,15 sti1–1::HIS3; and GS 115, his4 (Invitrogen).

All S. cerevisiae strains were grown in YPD medium (1% yeast extract, 2% bacto peptone, 2% glucose). The P. pastoris strain GS 115 containing the pPICZB-Ssa1 plasmid was grown in dextrose histidine medium (1.34% (w/v) yeast nitrogen base, 0.4% (w/v) L-histidine, 2% (w/v) glucose, 4 x 105% biotin), and the expression of Ssa1 was induced in methanol histidine medium (1.34% (w/v) yeast nitrogen base, 0.4% (w/v) L-histidine, 4 x 105% biotin, and 0.5% (v/v) methanol).

The lysates for immunoprecipitations were prepared as follows. The strains W303 and CN11a were grown in 100 ml of YPD medium to a A600 of ~1.0, harvested, and resuspended in 5 ml of 40 mM Hepes, pH 7.5, 150 mM KCl, 5 mM MgCl2. The cells were lysed using a cell disruption system (Constant Systems, Warwick, UK), shock frozen with liquid nitrogen, and stored in 100 µl portions at –80 °C.

Construction of pAS and pACT Clones—Ssa1–4, Ssb1–2, Sse1–2, Ssz1, and Sti1 were amplified by PCR using yeast genomic DNA (strain W303) and ligated in the vectors pAS1-CYH2 and/or pACTII (38) as fusion proteins with the GAL4 DNA-binding domain (pAS1-CYH2) and the GAL4 activation domain (pACTII) (Clontech, Palo Alto, CA). The identity of the clones was confirmed by DNA sequencing.

Two-hybrid Screening—The yeast strain Y190 was transformed with either Sti1 in pAS1-CYH2 or pACTII or the nine different yeast Hsp70s in pAS1-CYH2 or pACTII as described in the manufacturer's instructions (Clontech). Single transformants were confirmed as His and LacZ to ensure that the fusion proteins alone do not exhibit transcriptional activity in Y190. Double transformants were incubated for 3 days at 30 °C before positive clones were picked, restreaked onto His Leu Trp plates and assayed for the lacZ phenotype (39).

Construction of the Mutants his-Ssa1 (K69Q) and his-yHsp90 (E33A)—The design of the Ssa1 (K69Q) mutant is described elsewhere (40). The yHsp90 (E33A) point mutation was generated in vitro using overlap PCR technique according to Mikaelian and Sergeant (41). The identity of this construct was confirmed by DNA sequencing.

Protein Purification—S. cerevisiae Ssa1 was expressed using the P. pastoris expression system (42). The mutant his-Ssa1 (K69Q) was expressed and purified as described previously (40). Sti1 was expressed in the Escherichia coli strain BL21-CodonPlus (DE3) and purified as described elsewhere (28, 43). Wild type and mutant yHsp90 (E33A) were purified as described (44, 45). Human Hsp70 was expressed in a DnaK variant of the E. coli strain BL21-CodonPlus (DE3) and purified as described elsewhere (46). Human Hop and human Hsp90 were purified as described (44, 47). Shock frozen proteins were stored in 40 mM Hepes, pH 7.5, 150 mM KCl, 5 mM MgCl2, and 1 mM dithiothreitol (standard buffer) at –80 °C.

Immunoprecipitations—The immunoprecipitations were performed with lysates from the S. cerevisiae wild type strain W303 or the Sti1 knock-out strain CN11a and with the purified proteins Ssa1, Sti1, and yHsp90 in a volume of 100 µl. The immunoprecipitations were incubated at 25 °C for 1 h in standard buffer with or without 2 mM ATP, using the indicated antibodies. Immune complexes were recovered by binding to protein A/G-Sepharose (Sigma). After three washes with 5 volumes of 1x phosphate-buffered saline (4 mM KH2PO4, 16 mM Na2HPO4, 0.12 M NaCl, pH 7.4), the immunocomplexes were eluted with 1x Laemmli SDS loading buffer. For immunodetection, the proteins were separated by SDS-PAGE and transferred to Immobilon-nitrocellulose (Millipore, Bedford, MA) or Immobilon-polyvinylidene difluoride (Millipore) membranes and incubated with polyclonal anti-sera specific for either Ssa (C-terminal 80 amino acids), Ssb (C-terminal 80 amino acids) (48), Sti1 (this study), or yHsp90 (this study). As a secondary antibody, anti-rabbit IgG conjugated with peroxidase for ECL detection (Amersham Biosciences) was used.

ATPase Activity (Radioactive Assay)—ATPase assays were performed according to Kornberg et al. (49). The indicated amounts of Ssa1 ± Sti1 ± yHsp90 ± Ydj1 ± Hop, Hsp70 ± Hop ± Sti1, and Hsp90 ± Hop ± Sti1 (±, with or without) were incubated in standard buffer at 37 °C. The ATPase reaction was initiated by the addition of the respective ATP concentrations containing [{alpha}-32P]ATP (Hartmann Analytic, Braunschweig, Germany). A sample contained 0.1 µCi of [{alpha}-32P]ATP. As a control for unspecific protein effects, Sti1 was added after incubation at 70 °C for 30 min. For steady state hydrolysis measurements, a final ATP concentration of 15 mM was used. In the case of single turnover experiments, the ATP to protein ratio was kept constant at 0.8:1. The ATP to ADP ratio was quantified with a Typhoon 9200 PhosphorImager (Amersham Biosciences). The hydrolysis rates were corrected for uncatalyzed, spontaneous ATP hydrolysis.

ATPase Activity of Ssa1 (HPLC)—The formation of ADP in steady state and single turnover experiments was measured at 37 °C by incubating Ssa1 (Ssa1 K69Q) ± Sti1 and/or yHsp90 (yHsp90 E33A) with ATP for various times and subsequent nucleotide analysis by HPLC as described (50).

Biacore Measurements—Surface plasmon resonance (51, 52) data were collected on a Biacore X Instrument (Biacore, Uppsala, Sweden). For experiments in the yeast system, either Ssa1 or yHsp90 were covalently linked to the CM5 chip via amine residues according to the supplier's instructions; for determination of binding constants in the human system, Hop was linked the same way to the CM5 chip. The measurements were performed at a flow rate of 5 µl/min at 25 °C. To determine the binding constant, we directly measured the change in response units, when different amounts of Sti1 were injected onto a Ssa1- or yHsp90-coated chip in standard buffer with or without 2 mM ATP or different amounts of Hsp70 and Hsp90 were injected onto the Hop-coated chip in standard buffer with or without 2 mM ATP.

Data analysis for direct binding curves used the linear relationship between the resonance signal (RU) and the amount of protein (c) bound to the chip. RUmax (Equation 1) is the maximum signal at which all of the Ssa1 molecules on the chip are saturated with Sti1.

(Eq. 1)


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The Hsp70 Component of the Sti1 Complex Is the Ssa Proteins—An important step in characterizing the Hsp90 multichaperone complex in S. cerevisiae is to elucidate which of the 14 Hsp70 proteins present in yeast interacts with cytosolic Sti1.

Nine of the 14 different yeast Hsp70 proteins are cytosolic and therefore potential partners of the co-chaperone Sti1. It had been shown previously that at least one member of the Ssa class interacts with Sti1 in yeast (29), but it was not clear whether other yeast Hsp70s also interact with Sti1 in the Hsp90 system.

To determine which of these Hsp70 proteins interacts with Sti1, we tested Ssa1–4, Ssb1–2, Sse1–2, and Ssz1 in a yeast two-hybrid reporter system for interaction with Sti1 (Fig. 1 A). Only for the Ssa class (Ssa1–4) positive results were obtained suggesting that the Ssa proteins are the only Hsp70 component in the yHsp90 complex.



View larger version (29K):
[in this window]
[in a new window]
 
FIG. 1.
Identification of the Hsp70 component of the Sti1·yHsp90 chaperone complex. A, two-hybrid analysis. The pAS1-CYH2 plasmids containing nine different Hsp70 genes were transformed together with pACTII-Sti1 in the yeast strain Y190. The strains were grown for 2 days at 30 °C on His Leu Trp plates. After transfer to a nitrocellulose filter, the interactions were identified by {beta}-galactosidase activity (blue colonies). Only for the Ssa group, a positive result could be obtained. The reciprocal experiment yielded the same result (not shown). As a negative control, the plasmids were transformed separately in Y190. B, co-immunoprecipitations (IP). These experiments were performed at 25 °C with yeast lysate from the wild type strain W303 (lanes 1–3 and 5) supplemented with the indicated amounts of purified Sti1 or the Sti1 knock-out strain CN11a (lane 4). Sti1 was precipitated with a polyclonal Sti1 antibody, and the precipitate was analyzed using SDS-PAGE. The proteins were then transferred to a polyvinylidene difluoride membrane, and the Ssa or Ssb proteins were detected by Western blot analysis using anti-Ssa-IgG (lanes 1–4) or anti-Ssb-IgG (lanes 5 and 6). As a positive control for the presence of Ssb proteins in the strain W303, we performed a Western blot analysis of the lysate with anti-Ssb-IgG (lane 6). wt, wild type.

 

As an independent proof for this interaction, we immunoprecipitated Sti1 from a wild type yeast lysate (strain W303) and tested the precipitate by Western blotting for the presence of Ssa proteins. Fig. 1B (lane 1) shows that the Ssa proteins were precipitated together with Sti1. When the cell lysates were supplemented with purified Sti1, the amount of Ssa1 co-precipitated increased with increasing amounts of purified Sti1 added (Fig. 1B, lanes 2 and 3). As a control for the specificity of the Sti1 antibody, we repeated the experiment using lysate from the Sti1 knock-out strain CN11a (Fig. 1B, lane 4). No Ssa1 could be detected in this case. To test whether the Sti1 complex contained only Ssa proteins and not Ssb proteins, we probed the blots with an antibody specific for Ssb proteins. This experiment showed that Ssb proteins could not be detected in the Sti1 complex (Fig. 1B, lane 5). Ssb proteins were, however, present in the lysate as shown in Fig. 1B (lane 6). This result is in agreement with previous studies in the mammalian system (25), because only the Ssa class of Hsp70s share the C-terminal sequence motif (I/L/M)EEVD-COOH.

Because Ssa3 and Ssa4 are only expressed under heat shock, these proteins are not relevant for the function of the yHsp90 multichaperone complex under normal growth conditions. Therefore, we focused in the following on the Ssa1 protein, because Ssa1 and Ssa2 are 97% identical and expressed in equal amounts under these conditions (8).

Sti1 Binds to Ssa1 with Low Affinity—To further characterize the interaction between Ssa1 and Sti1, we purified both proteins and studied complex formation under physiological conditions concerning salt concentration and temperature.

First, we incubated the proteins and performed immunoprecipitations with anti-Sti1 or anti-Ssa antibodies and separated the precipitate by SDS-PAGE. Fig. 2A indicates that the Sti1-Ssa1 complex was formed efficiently under these conditions. We found that the amount of Ssa1 in the complex was not significantly affected by ATP (Fig. 2A, lanes 2 and 4).



View larger version (16K):
[in this window]
[in a new window]
 
FIG. 2.
In vitro analysis of Ssa1·Sti1 complexes. A, co-immunoprecipitations. The experiments were carried out at 25 °C with the purified proteins Ssa1 (5 µg) and Sti1 (5 µg) using polyclonal antibodies against Sti1 (lanes 1, 2, and 6) or Ssa1 (lanes 3–5). If present, ATP was added to a final concentration of 2 mM. The precipitate was separated by 4–12% SDS-PAGE. We found that the dimeric complex forms in the absence and presence of ATP. B, surface plasmon resonance analysis. These experiments were performed with Ssa1-coated chips as described in the experimental protocol. The plot shows the signal of binding (response units, RU) versus increasing Sti1 concentrations. The data points were fitted, and the dissociation constant KD was calculated as described in the experimental protocol. {circ}, – ATP;•, + 2 mM ATP.

 

To gain quantitative data on the interaction between Ssa1 and Sti1, surface plasmon resonance spectroscopy was employed. Binding of different Sti1 concentrations with or without ATP to immobilized Ssa1 was analyzed. The data from the resulting sensorgrams were used to determine the dissociation constant of the Ssa1-Sti1 interaction (Fig. 2B). We found that in the absence of ATP, Sti1 binds to Ssa1 with an affinity of 7.5 ± 2 µM, whereas in the presence of ATP, the affinity is 3 ± 1 µM (Fig. 2B and Table I). Compared with the affinity of Sti1 for yHsp90 (28, 43) (Table I), Sti1 binding to Ssa1 is about 2 orders of magnitude weaker.


View this table:
[in this window]
[in a new window]
 
TABLE I
Summary of KD values

The KD values were obtained by SPR spectroscopy as described under "Experimental Procedures." The experiments were performed in 40 mM Hepes, pH 7.5, 150 mM KCl, 5 mM MgCl2, and 1 mM dithiothreitol at 25 °C. For experiments in the yeast system, Ssa1 or yHsp90 were covalently linked to the CM5 chip via amine residues according to the supplier's instructions; for determination of binding constants for the homologous human proteins, Hop was linked to the CM5 chip. ND, not determined.

 

Sti1 Is a Potent Activator of the ATPase Activity of Ssa1—It has been described previously that Sti1 inhibits the ATPase activity of yHsp90 (28). We were interested in determining whether Sti1 influences the ATPase activity of Ssa1 as well. Sti1 itself does not exhibit ATPase activity (data not shown). The ATPase activity of Ssa1 is similar to that of other Hsp70s studied, with a Km for ATP of 0.2 µM and a kcat for ATP of 0.04 min1 at physiological potassium concentrations (48). When Sti1 was added to Ssa1, we found that, unexpectedly, the ATPase activity of Ssa1 increased with increasing amounts of Sti1 (Fig. 3A). A stimulation by a factor of 200 was reached at a Sti1:Ssa1 ratio of 1:1 (Fig. 3B). Half-maximal activation was reached at a ratio of Ssa1:Sti1 = 1:0.5. When thermally unfolded Sti1 was added in a control experiment, no significant increase in the ATPase activity of Ssa1 was detected (Table II).



View larger version (14K):
[in this window]
[in a new window]
 
FIG. 3.
Influence of Sti1 on the steady state and single turnover ATPase activity of Ssa1. Steady state and single turnover ATPase assays were carried out at 37 °C using [{alpha}-32P]ATP in the presence of increasing amounts of Sti1. In the case of steady state ATPase measurements, an excess of ATP was used, whereas in the case of single turnover experiments, the ratio of Ssa1:ATP was 1:0.8. The change in the ADP/ATP ratio was monitored over a time period of 60 min. No ATPase activity could be detected for Sti1 in the absence of Ssa1 and for the buffer alone. The same values were obtained with a nonradioactive method using HPLC analysis (data not shown) as described under "Experimental Procedures." A, {circ},30 µM Ssa1 alone; •,30 µM Ssa1/3 µM Sti1; {blacksquare}, 30 µM Ssa1/30 µM Sti1. B, stimulation of the steady state ATPase activity of Ssa1 (30 µM) in the presence of increasing amounts of Sti1. Note that the ATPase activity in the absence of Sti1 is 0.04 min1. C, stimulation of the single turnover ATPase activity of Ssa1 (30 µM) in the presence of increasing amounts of Sti1. Note that the ATPase activity in the absence of Sti1 is 0.04 min1.

 

View this table:
[in this window]
[in a new window]
 
TABLE II
Summary of kcat values

The kcat values were determined as described under "Experimental Procedures." For Ssa1 and hHsp90, a concentration of 30 µM each was used and for yHsp90 and Hsp70, a concentration of 5 µM each was used. The respective ratios are indicated.

 

To determine which step in the Ssa1 ATPase cycle is accelerated by Sti1, we compared steady state measurements with single turnover experiments in the presence and absence of Sti1 (Fig. 3). It was not known whether ATP hydrolysis or nucleotide exchange represents the rate-limiting step in the ATPase cycle of Ssa1. To discriminate between the two possibilities, we analyzed the steady state kcat and the single turnover kcat. In steady state measurements, excess of ATP is used, and therefore Ssa1 hydrolyzes ATP with maximum velocity, whereas in single turnover assays, about 80% of Ssa1 is saturated with ATP. Thus, a single hydrolysis step could be monitored, which allows, in comparison with the steady state measurement, determination of the rate-limiting step of the ATPase cycle. We found that the kcat values (0.04 min1) were identical in the absence of Sti1. Thus, we conclude that ATP hydrolysis, or a conformational change preceding it, is rate-limiting for the Ssa1 ATPase cycle. Increasing amounts of Sti1 resulted in an acceleration of the single turnover ATPase activity of Ssa1 (Fig. 3C). A stimulation factor of 200 could also be seen in the single turnover experiments at a Sti1 to Ssa1 ratio of 1:1. In the presence of Sti1, both the steady state kcat and the single turnover kcat were accelerated (Fig. 3). This demonstrates that Sti1 stimulates ATP hydrolysis and confirms that this step is rate-limiting in the Ssa1 ATPase cycle.

As previously described (53), Ydj1 is able to accelerate the ATPase of Ssa1 by a factor of 10. When Ydj1 was added to a preformed Ssa1-Sti1 complex at a 1:1 ratio or at high excess, the activation resulting from Sti1 was not influenced (data not shown). Further, if Sti1 was added to an Ssa1-Ydj1 complex, a 200-fold activation was observed.

Influence of Sti1 on Ssa1 and yHsp90 in the Ternary Multichaperone Complex—To study the ternary multichaperone complex consisting of Ssa1, Sti1, and yHsp90, we incubated the purified Ssa1, Sti1, and yHsp90, precipitated with anti-Ssa1, anti-Sti1 or anti-yHsp90 antibodies and separated the precipitate by SDS-PAGE (Fig. 4A). The three proteins could be detected in equal amounts no matter which antibody was used. This complex is also present in the absence of ATP (Fig. 4A, lane 4).



View larger version (14K):
[in this window]
[in a new window]
 
FIG. 4.
Analysis of complexes between Ssa1, Sti1, and yHsp90 in vitro. A, co-immunoprecipitations. These experiments were carried out at 25 °C with the purified proteins Ssa1 (5 µg), Sti (5 µg), and yHsp90 (5 µg) using polyclonal antibodies against Sti1 (lanes 1 and 5), Ssa1 (lanes 2 and 6), or yHsp90 (lanes 3, 4, and 7). If present, ATP was added to a final concentration of 2 mM. The precipitate was separated by 4–12% SDS-PAGE. We found that the ternary complex forms in the absence and presence of ATP. B, ATPase effects in the ternary multichaperone complex. ATPase assays were carried out at 37 °C using [{alpha}-32P]ATP. The ratio of [Ssa1]:[Sti1] was 5:1, and the ratio of [yHsp90]:[Sti1] was 1:5. The ratio in the ternary complexes [Ssa1]:[Sti1]:[yHsp90] was 25:5:1. To determine the effects in the ternary complex, Ssa1 and yHsp90 were replaced by the respective ATPase mutants Ssa1(K69Q) and yHsp90(E33A). The reactions were incubated for 120 min, and changes in the ADP/ATP ratios were monitored. The effect of Sti1 on the Ssa1 and yHsp90 ATPase activities in the ternary complex seems to be the same as in the dimeric complexes.

 

To study the influence of Sti1 on the ATPase activities of yHsp90 and Ssa1 in the ternary complex, it was necessary to incorporate either a Ssa1 mutant (K69Q) (40) or a yHsp90 mutant (E33A) (54, 55), both of which are defective in ATP hydrolysis in the complex. Using these variants, complex formation with Sti1 was not affected (data not shown). When we analyzed the ATPase activity of Ssa1 in a Ssa1-Sti1-yHsp90(E33A) complex and the ATPase activity of yHsp90 in a Ssa1(K69Q)-Sti1-yHsp90 complex, we could not detect any difference compared with the respective binary wild type complexes (Fig. 4B). Thus, the effect of Sti1 on the Ssa1 and yHsp90 ATPase activities in the ternary complex seems to be the same as in the dimeric complexes.

Comparison with the Mammalian System—Taken together, our results clearly show that Sti1 accelerates the ATPase activity of Ssa1. This is in contrast with previous studies on the function of Hop in the mammalian system. Here, Hop did not exhibit an effect on the ATPase activity of Hsp70 (56). To directly compare the yeast with the mammalian system, we purified the mammalian proteins. First, we determined the binding constants between Hsp70, Hop, and human Hsp90 (hHsp90) by surface plasmon resonance spectroscopy. As can be seen in Table I, Hsp70 binds with low affinity (KD = 1.5 µM) to Hop. The affinity is increased in the presence of hHsp90 (KD = 0.3 µM). hHsp90 binds with higher affinity to Hop (KD = 0.1 µM), and the binding is not affected by Hsp70. The values are comparable with previously published data determined by other experimental procedures (57).

These data allowed us to perform ATPase experiments under conditions where the respective proteins are associated. The steady state ATPase activities of hHsp90 and Hsp70 were determined to be 0.04 and 0.4 min1, respectively. This is in the range of previously published results (58, 59). In agreement with data from Johnson et al. (56), our experiments show that Hop does not influence the ATPase activity of Hsp70 or that of hHsp90 (Table II).

To test whether the effect of Sti1 is specific for Ssa1 and yHsp90, we analyzed the influence of Sti1 on the ATPase activities of Hsp70 and hHsp90 and the influence of Hop on the ATPase activities of Ssa1 and yHsp90 (Table II). We found that Sti1 influenced neither the ATPase activity of Hsp70 nor that of hHsp90, even if added in high excess. Furthermore, the experiments showed that Hop had no influence on the ATPase activity of Ssa1 or yHsp90.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
In eukaryotes, multiple Hsp70s exist in one compartment. This highlights the functional diversity of these proteins. In yeast, the subgroups Ssa, Ssb, Sse, and Ssz are present in the cytosol. However, as we show here, only the Ssa class is involved in cooperation with the yHsp90 chaperone machinery. This allows specific regulation of one subset of Hsp70s.

Co-chaperones, which modulate Hsp70 function, have been extensively studied for E. coli DnaK. DnaK is regulated by DnaJ, which stimulates the ATP hydrolysis step in the DnaK ATPase cycle (60), yielding the high affinity ADP state for substrate binding and GrpE, which functions as a nucleotide exchange factor for release of substrate and allows the cycle to begin anew (61, 62). The only yeast co-chaperones reported so far that have a stimulatory effect on the ATPase activity of Ssa1 are Ydj1 and Sis1, which belong to the DnaJ/Hsp40 family. They activate the ATPase activity of Ssa1 about 10-fold by catalyzing the ATP hydrolysis step in the Ssa1 ATPase cycle (53, 63, 64).

More divergent are GrpE homologues, which have so far only been identified in prokaryotes (65) and mitochondria (66). The eukaryotic protein Bag-1, which is discussed as a nucleotide release factor of Hsp70 (67), regulates the activity of Hsp70 proteins by binding to the N-terminal ATPase domain of Hsp70 (68). Snl1 from S. cerevisiae may be the yeast homologue of Bag-1 (69). In previous studies, a protein with similarity to Hop from rabbit reticulocyte lysate was shown to activate the ATPase of Hsp70 about 7-fold (70, 71) by stimulating nucleotide exchange, which implies that this protein activates Hsp70 through a GrpE-like mechanism. Hop itself does not have an influence on the ATPase activity of Hsp70 in the mammalian system (56).

Sti1 is a new member of the family of Hsp70 ATPase modulators. Sti1 is composed of three TPR domains. TPR domains are loosely conserved repeats of roughly 34 amino acids known to mediate protein-protein interactions (24, 25). In Hop and Sti1, they serve to link Hsp70 and Hsp90 (1, 72). The N-terminal TPR domain of Hop interacts with Hsp70, and the TPR domains in the C-terminal half seem to be important for the interaction with Hsp90 (25). We show here that Sti1 is a potent activator of the ATPase activity of Ssa1. Sti1 does not exhibit significant sequence homology to the DnaJ or GrpE class. Interestingly, as described above, all of the stimulation factors known for Ssa1, including peptides, show no more than 10-fold activation, whereas Sti1 increases the overall ATPase activity of Ssa1 up to 200-fold. Comparing steady state and single turnover ATP hydrolysis, we show that the hydrolysis step or conformational rearrangements preceding it are rate-limiting for the Ssa1 ATPase cycle. Sti1 specifically accelerates this step. Thus, Sti1 is the first "non-DnaJ" activator of this step. Moreover, Sti1 is able to activate Ssa1, even if Ssa1 is already stimulated maximally by Ydj1, and Ydj1 is not able to replace Sti1 in a preformed Ssa1-Sti1 complex, even if added in high excess. Therefore, we conclude that Sti1 and Ydj1 have separate, unique binding sites on Ssa1. Further, we show that binding of Sti1 to yHsp90 and Ssa1 allows to activate Hsp70 and inhibit Hsp90 at the same time.

Our studies of the yeast and mammalian proteins show that Sti1 acts differently from Hop. Whereas Hop only seems to act as a passive linker protein between Hsp70 and hHsp90 (1), Sti1 is a regulatory linker protein for Ssa1 and yHsp90. It is able to activate the ATPase activity of Ssa1 and inhibit the ATPase activity of yHsp90 at the same time. Moreover the experiments with mixed complexes between yeast and human components show that the effect of Sti1 on Ssa1 is specific, because Hop has no influence on the ATPase activity of Ssa1, and Sti1 has no influence on the ATPase activity of Hsp70. Because the ATPase activity of Hsp70s can be stimulated by peptides and denatured protein substrates, the formal possibility existed that Sti1 binds unspecifically to the substrate-binding site of Ssa1 and stimulates ATP hydrolysis this way rather than being an allosteric effector. However, the analysis of the effect of unfolded Sti1 on Ssa1 and the finding that Sti1 does not influence human Hsp70 allow direct exclusion of this possibility. Therefore, we conclude that Sti1 acts as a specific activator of Ssa1.

This raises the question of how the regulation of Hsp70 and Hsp90 is accomplished in the context of the human Hsp90 system. Interestingly, the basic ATPase activity of hHsp90 is 10-fold weaker compared with yHsp90, and the ATPase activity of Hsp70 is about 10-fold higher compared with Ssa1. Thus, compared with the yeast system, Hsp70 is already activated, and hHsp90 is inhibited. Therefore, different modes of regulation may be required for the human system.

For the yeast system, clearly, the role of Sti1 in the Hsp90 chaperone cycle is not only that of a scaffold protein for Hsp70 and Hsp90 but also that of a chimeric regulator for both proteins, which changes the state of activity of the two components several hundred-fold. In the Hsp90 chaperone cycle, Hsp70 is the first component of the Hsp90 complex that can be co-precipitated with steroid hormone receptors (20). Hsp90 and Sti1/Hop then join the complex. We suggest that the differential regulation of the ATPase activities of both yHsp90 and Ssa1 by Sti1 is the basis for the committing step of the yeast Hsp90 chaperone cycle.


    FOOTNOTES
 
* This work was supported by grants of the Deutsche Forschungsgemeinschaft and the Fonds der Chemischen Industrie (to J. B. and J. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ Supported by fellowships of the Studienstiftung des Deutschen Volkes and the Fonds der Chemischen Industrie. Back

|| To whom correspondence should be addressed: Technische Universität München, Institut für Organische Chemie & Biochemie, Lichtenbergstr. 4, D-85747 Garching, Germany. Tel.: 49-89-289-13341; Fax: 49-89-289-13345; E-mail: johannes.buchner{at}ch.tum.de.

1 The abbreviations used are: TPR, tetratricopeptide repeat; HPLC, high pressure liquid chromatography; yHsp90, yeast Hsp90; hHsp90, human Hsp90. Back


    ACKNOWLEDGMENTS
 
Ssa and Ssb antibodies were kindly provided by Elizabeth Craig (University of Wisconsin, Madison, WI). The Sti1 knock-out strain CN11a from Susan Lindquist (Massachusetts Institute of Technology, Cambridge, MA), the Ssa1 ATPase mutant strain from Jeff Brodsky (University of Pittsburgh, Pittsburgh, PA), the Hsp70 plasmid from Maciej Zylicz (International Institute of Molecular and Cell Biology, Warsaw, Poland), the Hop/p60 clone from David Smith (Mayo Clinic, Scottsdale, AZ), and the Sf9-infected cells containing human Hsp90 from Kurt Christensen (University of Colorado, Cancer Center, Denver, CO) were kind gifts. We gratefully acknowledge the experimental help of Barbara Fürnrohr, Sebastian Wandinger, Alexander Frenzel, Lin Müller, and Petra Herde and thank Stefan Walter and Thomas Scheibel for reading the manuscript.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Smith, D. F., and Toft, D. O. (1993) Mol. Endocrinol. 7, 4–11[Medline] [Order article via Infotrieve]
  2. Pratt, W. B., and Toft, D. O. (1997) Endocr. Rev. 18, 306–360[Abstract/Free Full Text]
  3. Buchner, J. (1999) Trends Biochem. Sci. 24, 136–141[CrossRef][Medline] [Order article via Infotrieve]
  4. Jolly, C., and Morimoto, R. I. (2000) J. Natl. Cancer Inst. 92, 1564–1572[Abstract/Free Full Text]
  5. Richter, K., and Buchner, J. (2001) J. Cell. Physiol. 188, 281–290[CrossRef][Medline] [Order article via Infotrieve]
  6. Zylicz, M., King, F. W., and Wawrzynow, A. (2001) EMBO J. 20, 4634–4638[Free Full Text]
  7. Walter, S., and Buchner, J. (2002) Angew. Chem. Int. Ed. Engl. 41, 1098–1113[CrossRef][Medline] [Order article via Infotrieve]
  8. Craig, E. A., Boorstein, W. R., Park, H. O., and Stone, D. N. C. M. (1989) UCLA Symp. Mol. Cell. Biol. 96, 51–61
  9. Bukau, B., and Horwich, A. L. (1998) Cell 92, 351–366[Medline] [Order article via Infotrieve]
  10. Georgopoulos, C., and Welch, W. J. (1993) Annu. Rev. Cell Biol. 9, 601–634[CrossRef][Medline] [Order article via Infotrieve]
  11. Parsell, D. A., and Lindquist, S. (1994) The Biology of Heat Shock Proteins and Molecular Chaperones, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  12. Mayer, M. P., and Bukau, B. (1999) Curr. Biol. 9, R322–5R325[CrossRef][Medline] [Order article via Infotrieve]
  13. Donze, O., and Picard, D. (1999) Mol. Cell. Biol. 19, 8422–8432[Abstract/Free Full Text]
  14. Donze, O., Abbas-Terki, T., and Picard, D. (2001) EMBO J. 20, 3771–3780[Abstract/Free Full Text]
  15. Young, J. C., Moarefi, I., and Hartl, F. U. (2001) J. Cell Biol. 154, 267–273[Abstract/Free Full Text]
  16. Picard, D., Bunone, G., Liu, J. W., and Donze, O. (1997) Biochem. Soc. Trans. 25, 597–602[Medline] [Order article via Infotrieve]
  17. Picard, D. (2002) Cell Mol. Life Sci. 59, 1640–1648[Medline] [Order article via Infotrieve]
  18. Dalman, F. C., Bresnick, E. H., Patel, P. D., Perdew, G. H., Watson, S. J., Jr., and Pratt, W. B. (1989) J. Biol. Chem. 264, 19815–19821[Abstract/Free Full Text]
  19. Scherrer, L. C., Dalman, F. C., Massa, E., Meshinchi, S., and Pratt, W. B. (1990) J. Biol. Chem. 265, 21397–21400[Abstract/Free Full Text]
  20. Smith, D. F., Schowalter, D. B., Kost, S. L., and Toft, D. O. (1990) Mol. Endocrinol. 4, 1704–1711[Abstract]
  21. Perdew, G. H., and Whitelaw, M. L. (1991) J. Biol. Chem. 266, 6708–6713[Abstract/Free Full Text]
  22. Smith, D. F., Stensgard, B. A., Welch, W. J., and Toft, D. O. (1992) J. Biol. Chem. 267, 1350–1356[Abstract/Free Full Text]
  23. Dittmar, K. D., and Pratt, W. B. (1997) J. Biol. Chem. 272, 13047–13054[Abstract/Free Full Text]
  24. Honore, B., Leffers, H., Madsen, P., Rasmussen, H. H., Vandekerckhove, J., and Celis, J. E. (1992) J. Biol. Chem. 267, 8485–8491[Abstract/Free Full Text]
  25. Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U., and Moarefi, I. (2000) Cell 101, 199–210[Medline] [Order article via Infotrieve]
  26. Dittmar, K. D., Hutchison, K. A., Owens-Grillo, J. K., and Pratt, W. B. (1996) J. Biol. Chem. 271, 12833–12839[Abstract/Free Full Text]
  27. Chen, S., and Smith, D. F. (1998) J. Biol. Chem. 273, 35194–35200[Abstract/Free Full Text]
  28. Prodromou, C., Siligardi, G., O'Brien, R., Woolfson, D. N., Regan, L., Panaretou, B., Ladbury, J. E., Piper, P. W., and Pearl, L. H. (1999) EMBO J. 18, 754–762[Abstract/Free Full Text]
  29. Chang, H. C., and Lindquist, S. (1994) J. Biol. Chem. 269, 24983–24988[Abstract/Free Full Text]
  30. Werner-Washburne, M., Stone, D. E., and Craig, E. A. (1987) Mol. Cell. Biol. 7, 2568–2577[Medline] [Order article via Infotrieve]
  31. Nelson, R. J., Ziegelhoffer, T., Nicolet, C., Werner-Washburne, M., and Craig, E. A. (1992) Cell 71, 97–105[Medline] [Order article via Infotrieve]
  32. Pfund, C., Lopez-Hoyo, N., Ziegelhoffer, T., Schilke, B. A., Lopez-Buesa, P., Walter, W. A., Wiedmann, M., and Craig, E. A. (1998) EMBO J. 17, 3981–3989[Abstract/Free Full Text]
  33. Craig, E. A., and Jacobsen, K. (1985) Mol. Cell. Biol. 5, 3517–3524[Medline] [Order article via Infotrieve]
  34. Gautschi, M., Lilie, H., Funfschilling, U., Mun, A., Ross, S., Lithgow, T., Rucknagel, P., and Rospert, S. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 3762–3767[Abstract/Free Full Text]
  35. Gautschi, M., Mun, A., Ross, S., and Rospert, S. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 4209–4214[Abstract/Free Full Text]
  36. Hundley, H., Eisenman, H., Walter, W., Evans, T., Hotokezaka, Y., Wiedmann, M., and Craig, E. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 4203–4208[Abstract/Free Full Text]
  37. Mukai, H., Kuno, T., Tanaka, H., Hirata, D., Miyakawa, T., and Tanaka, C. (1993) Gene (Amst.) 132, 57–66[CrossRef][Medline] [Order article via Infotrieve]
  38. Sambrook, J., and Russell, D. W. (2001) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  39. Breeden, L., and Nasmyth, K. (1985) Cold Spring Harbor Symp. Quant. Biol. 50, 643–650[Medline] [Order article via Infotrieve]
  40. McClellan, A. J., and Brodsky, J. L. (2000) Genetics 156, 501–512[Abstract/Free Full Text]
  41. Mikaelian, I., and Sergeant, A. (1992) Nucleic Acids Res. 20, 376[Medline] [Order article via Infotrieve]
  42. Wegele, H., Haslbeck, M., and Buchner, J. (2003) J. of Chromatogr. B 786, 109–115[CrossRef]
  43. Mayr, C., Richter, K., Lilie, H., and Buchner, J. (2000) J. Biol. Chem. 275, 34140–34146[Abstract/Free Full Text]
  44. Buchner, J., Bose, S., Mayr, C., and Jakob, U. (1998) Methods Enzymol. 290, 409–418[Medline] [Order article via Infotrieve]
  45. Richter, K., Muschler, P., Hainzl, O., and Buchner, J. (2001) J. Biol. Chem. 276, 33689–33696[Abstract/Free Full Text]
  46. Schumacher, R. J., Hansen, W. J., Freeman, B. C., Alnemri, E., Litwack, G., and Toft, D. O. (1996) Biochemistry 35, 14889–14898[CrossRef][Medline] [Order article via Infotrieve]
  47. Buchner, J., Weikl, T., Bugl, H., Pirkl, F., and Bose, S. (1998) Methods Enzymol. 290, 418–429[Medline] [Order article via Infotrieve]
  48. Lopez-Buesa, P., Pfund, C., and Craig, E. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 15253–15258[Abstract/Free Full Text]
  49. Kornberg, A., Scott, J. F., and Bertsch, L. L. (1978) J. Biol. Chem. 253, 3298–3304[Abstract]
  50. Theyssen, H., Schuster, H. P., Packschies, L., Bukau, B., and Reinstein, J. (1996) J. Mol. Biol. 263, 657–670[CrossRef][Medline] [Order article via Infotrieve]
  51. Schuck, P. (1997) Curr. Opin. Biotechnol. 8, 498–502[CrossRef][Medline] [Order article via Infotrieve]
  52. Nice, E. C., and Catimel, B. (1999) Bioessays 21, 339–352[CrossRef][Medline] [Order article via Infotrieve]
  53. Cyr, D. M., Lu, X., and Douglas, M. G. (1992) J. Biol. Chem. 267, 20927–20931[Abstract/Free Full Text]
  54. Obermann, W. M., Sondermann, H., Russo, A. A., Pavletich, N. P., and Hartl, F. U. (1998) J. Cell Biol. 143, 901–910[Abstract/Free Full Text]
  55. Panaretou, B., Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., and Pearl, L. H. (1998) EMBO J. 17, 4829–4836[Abstract/Free Full Text]
  56. Johnson, B. D., Schumacher, R. J., Ross, E. D., and Toft, D. O. (1998) J. Biol. Chem. 273, 3679–3686[Abstract/Free Full Text]
  57. Hernandez, M. P., Sullivan, W. P., and Toft, D. O. (2002) J. Biol. Chem. 277, 38294–38304[Abstract/Free Full Text]
  58. McLaughlin, S. H., Smith, H. W., and Jackson, S. E. (2002) J. Mol. Biol. 315, 787–798[CrossRef][Medline] [Order article via Infotrieve]
  59. Ha, J. H., Johnson, E. R., McKay, D. B., Sousa, M. C., Takeda, S., and Wilbanks, S. M. (1999) in Molecular Chaperones and Folding Catalysts: Regulation, Cellular Functions and Mechanisms (Bukau, B., ed) pp. 573–607, Harvard Academic Publisher, Boston, MA
  60. McCarty, J. S., Buchberger, A., Reinstein, J., and Bukau, B. (1995) J. Mol. Biol. 249, 126–137[CrossRef][Medline] [Order article via Infotrieve]
  61. Liberek, K., Marszalek, J., Ang, D., Georgopoulos, C., and Zylicz, M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 2874–2878[Abstract]
  62. Packschies, L., Theyssen, H., Buchberger, A., Bukau, B., Goody, R. S., and Reinstein, J. (1997) Biochemistry 36, 3417–3422[CrossRef][Medline] [Order article via Infotrieve]
  63. Lu, Z., and Cyr, D. M. (1998) J. Biol. Chem. 273, 27824–27830[Abstract/Free Full Text]
  64. Craig, E. A., Yan, W., and James, P. (1999) in Molecular Chaperones and Folding Catalysts: Regulation, Cellular Functions and Mechanisms (Bukau, B., ed) pp. 139–162, Harvard Academic Publishers, Boston, MA
  65. Wetzstein, M., Volker, U., Dedio, J., Lobau, S., Zuber, U., Schiesswohl, M., Herget, C., Hecker, M., and Schumann, W. (1992) J. Bacteriol. 174, 3300–3310[Abstract]
  66. Laloraya, S., Dekker, P. J., Voos, W., Craig, E. A., and Pfanner, N. (1995) Mol. Cell. Biol. 15, 7098–7105[Abstract]
  67. Hohfeld, J., and Jentsch, S. (1997) EMBO J. 16, 6209–6216[Abstract/Free Full Text]
  68. Nollen, E. A., Brunsting, J. F., Song, J., Kampinga, H. H., and Morimoto, R. I. (2000) Mol. Cell. Biol. 20, 1083–1088[Abstract/Free Full Text]
  69. Sondermann, H., Ho, A. K., Listenberger, L. L., Siegers, K., Moarefi, I., Wente, S. R., Hartl, F. U., and Young, J. C. (2002) J. Biol. Chem. 277, 33220–33227[Abstract/Free Full Text]
  70. Gross, M., and Hessefort, S. (1996) J. Biol. Chem. 271, 16833–16841[Abstract/Free Full Text]
  71. Gross, M., Hessefort, S., Olin, A., and Reddy, G. (1996) J. Biol. Chem. 271, 16842–16849[Abstract/Free Full Text]
  72. Chang, H. C., Nathan, D. F., and Lindquist, S. (1997) Mol. Cell. Biol. 17, 318–325[Abstract]